
News|Videos|March 30, 2026
Q1 2026 recap: Top videos in pediatric care
Author(s)Celeste Krewson, Assistant Editor
Fact checked by: Yasmeen Qahwash
As we step into Q2 2026, take a look back at our top video interviews and packages of Q1.
Advertisement
Advertisement
Throughout the first quarter of 2026, our coverage at Contemporary Pediatrics has highlighted a broad spectrum of critical updates and emerging research across diverse therapeutic areas. Key focal points include evaluating demographic disparities in oral food challenge completion rates, assessing the safety and efficacy profile of tapinarof cream in pediatric atopic dermatitis, and examining the clinical implications of the newly updated US Dietary Guidelines.
Related to this article

At ACAAI 2026, 93.6% of pediatric biologic prescriptions needed prior authorization, 39.3% were denied, and approval took a mean of 33 days.

Schools without stock epinephrine were over 4 times as likely to lack a device in an allergic emergency, a survey of 349 school nurses found.

In a matched cohort of children aged 6 and younger with EoE, dupilumab was linked to less incident asthma than swallowed budesonide (10.5% vs 16.2%).

Non-English-speaking families were far less likely to introduce peanut by 6 months (OR, 0.21) in a 3,170-child study presented at ACAAI 2026.

In an ACAAI 2026 survey, 85% of clinicians knew food allergy panels often yield false positives, yet many ordered them for unvalidated uses.

A meta-analysis of 7 real-world studies found maternal RSVpreF 78% effective against RSV LRTI hospitalization in infants up to 6 months.

New real-world data reveal delays and disparities in nirsevimab administration, highlighting opportunities to improve timely RSV protection for infants.
Advertisement
Advertisement

